Raboud J - Search Results

1

Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.

Raboud J, Blitz S, Walmsley S, Thompson C, Rourke SB, Loutfy MR; Ontario HIV Treatment Network Cohort Study Team. Raboud J, et al. HIV Clin Trials. 2010 Nov-Dec;11(6):340-50. doi: 10.1310/hct1106-340. HIV Clin Trials. 2010. PMID: 21239362

2

Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients.

Raboud JM, Rae S, Woods R, Harris M, Montaner JS; INCAS and AVANTI Study Groups. Raboud JM, et al. AIDS. 2002 Aug 16;16(12):1627-32. doi: 10.1097/00002030-200208160-00008. AIDS. 2002. PMID: 12172084 Clinical Trial.

3

Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.

Loutfy M, Raboud J, Thompson C, Tseng A, Abdurrahman Z, Kovacs C, Rachlis A, Phillips E, Rubin G, Gough K, Walmsley S. Loutfy M, et al. Among authors: raboud j. HIV Clin Trials. 2003 Sep-Oct;4(5):301-10. doi: 10.1310/7LYW-GQFF-WPRQ-K3QW. HIV Clin Trials. 2003. PMID: 14583846

4

Rosiglitazone for HIV-1 lipoatrophy.

Cavalcanti RB, Raboud J, Kain KC, Walmsley S. Cavalcanti RB, et al. Among authors: raboud j. Lancet. 2004 May 29;363(9423):1828-9; author reply 1829. doi: 10.1016/S0140-6736(04)16318-6. Lancet. 2004. PMID: 15172791 No abstract available.

5

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR. Loutfy MR, et al. Antivir Ther. 2004 Aug;9(4):595-602. Antivir Ther. 2004. PMID: 15456091

6

Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada.

Raboud JM, Abdurrahman ZB, Major C, Millson P, Robinson G, Rachlis A, Bayoumi AM. Raboud JM, et al. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):327-32. doi: 10.1097/01.qai.0000143603.94728.b2. J Acquir Immune Defic Syndr. 2005. PMID: 15980694

7

Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research.

Cavalcanti RB, Cheung AM, Raboud J, Walmsley S. Cavalcanti RB, et al. Among authors: raboud j. J Clin Densitom. 2005 Fall;8(3):293-7. doi: 10.1385/jcd:8:3:293. J Clin Densitom. 2005. PMID: 16055959

8

Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis.

Walmsley SL, Raboud J, Angel JB, Mazzulli T, Shen S, Casciaro L, Young CD, Moussa G, Gough K, Rachlis A, Hopkins J. Walmsley SL, et al. Among authors: raboud j. HIV Clin Trials. 2006 Jan-Feb;7(1):1-9. doi: 10.1310/9M23-QN0X-W6N8-80JD. HIV Clin Trials. 2006. PMID: 16632459 Clinical Trial.

9

Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors.

Tan D, Walmsley S, Shen S, Raboud J. Tan D, et al. Among authors: raboud j. HIV Clin Trials. 2006 May-Jun;7(3):107-15. doi: 10.1310/95VE-A6KJ-WRQ0-1F8Y. HIV Clin Trials. 2006. PMID: 16880167 Clinical Trial.

10

A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.

Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. Cavalcanti RB, et al. Among authors: raboud j. J Infect Dis. 2007 Jun 15;195(12):1754-61. doi: 10.1086/518005. Epub 2007 May 2. J Infect Dis. 2007. PMID: 17492590 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

286 results

Search Page

Filters